Type 2 Diabetes and ADP Receptor Blocker Therapy
Type 2 diabetes (T2D) is associated with several abnormalities in haemostasis predisposing to thrombosis. Moreover, T2D was recently connected with a failure in antiplatelet response to clopidogrel, the most commonly used ADP receptor blocker in clinical practice. Clopidogrel high on-treatment plate...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2016/6760710 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832558278316392448 |
|---|---|
| author | Matej Samoš Marián Fedor František Kovář Michal Mokáň Tomáš Bolek Peter Galajda Peter Kubisz Marián Mokáň |
| author_facet | Matej Samoš Marián Fedor František Kovář Michal Mokáň Tomáš Bolek Peter Galajda Peter Kubisz Marián Mokáň |
| author_sort | Matej Samoš |
| collection | DOAJ |
| description | Type 2 diabetes (T2D) is associated with several abnormalities in haemostasis predisposing to thrombosis. Moreover, T2D was recently connected with a failure in antiplatelet response to clopidogrel, the most commonly used ADP receptor blocker in clinical practice. Clopidogrel high on-treatment platelet reactivity (HTPR) was repeatedly associated with the risk of ischemic adverse events. Patients with T2D show significantly higher residual platelet reactivity on ADP receptor blocker therapy and are more frequently represented in the group of patients with HTPR. This paper reviews the current knowledge about possible interactions between T2D and ADP receptor blocker therapy. |
| format | Article |
| id | doaj-art-d679b223b0154638a190e31ba3be1814 |
| institution | Kabale University |
| issn | 2314-6745 2314-6753 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-d679b223b0154638a190e31ba3be18142025-02-03T01:32:47ZengWileyJournal of Diabetes Research2314-67452314-67532016-01-01201610.1155/2016/67607106760710Type 2 Diabetes and ADP Receptor Blocker TherapyMatej Samoš0Marián Fedor1František Kovář2Michal Mokáň3Tomáš Bolek4Peter Galajda5Peter Kubisz6Marián Mokáň7Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, SlovakiaNational Center of Hemostasis and Thrombosis, Department of Hematology and Blood Transfusion, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, SlovakiaDepartment of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, SlovakiaDepartment of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, SlovakiaDepartment of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, SlovakiaDepartment of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, SlovakiaNational Center of Hemostasis and Thrombosis, Department of Hematology and Blood Transfusion, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, SlovakiaDepartment of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, SlovakiaType 2 diabetes (T2D) is associated with several abnormalities in haemostasis predisposing to thrombosis. Moreover, T2D was recently connected with a failure in antiplatelet response to clopidogrel, the most commonly used ADP receptor blocker in clinical practice. Clopidogrel high on-treatment platelet reactivity (HTPR) was repeatedly associated with the risk of ischemic adverse events. Patients with T2D show significantly higher residual platelet reactivity on ADP receptor blocker therapy and are more frequently represented in the group of patients with HTPR. This paper reviews the current knowledge about possible interactions between T2D and ADP receptor blocker therapy.http://dx.doi.org/10.1155/2016/6760710 |
| spellingShingle | Matej Samoš Marián Fedor František Kovář Michal Mokáň Tomáš Bolek Peter Galajda Peter Kubisz Marián Mokáň Type 2 Diabetes and ADP Receptor Blocker Therapy Journal of Diabetes Research |
| title | Type 2 Diabetes and ADP Receptor Blocker Therapy |
| title_full | Type 2 Diabetes and ADP Receptor Blocker Therapy |
| title_fullStr | Type 2 Diabetes and ADP Receptor Blocker Therapy |
| title_full_unstemmed | Type 2 Diabetes and ADP Receptor Blocker Therapy |
| title_short | Type 2 Diabetes and ADP Receptor Blocker Therapy |
| title_sort | type 2 diabetes and adp receptor blocker therapy |
| url | http://dx.doi.org/10.1155/2016/6760710 |
| work_keys_str_mv | AT matejsamos type2diabetesandadpreceptorblockertherapy AT marianfedor type2diabetesandadpreceptorblockertherapy AT frantisekkovar type2diabetesandadpreceptorblockertherapy AT michalmokan type2diabetesandadpreceptorblockertherapy AT tomasbolek type2diabetesandadpreceptorblockertherapy AT petergalajda type2diabetesandadpreceptorblockertherapy AT peterkubisz type2diabetesandadpreceptorblockertherapy AT marianmokan type2diabetesandadpreceptorblockertherapy |